5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Jubilant Pharmova Ltd.

•
jubilantpharmova.comBSE: 530019NSE: JUBLPHARMA
Market Cap₹ 16,328 Cr.
Current Price
High / Low₹ 1,185 / 786
Stock P/E46.4
Book Value₹ 448
Price to Book1.82
Dividend Yield0.49 %
ROCE8.7 %
ROE6.0 %
Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Radiopharma: 44.3% • Contract Development & Manufacturing Organisation Sterile Injectables: 21.7% • Contract Research & Development Services: 15.2%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 2.50x)
  • Company has a consistent dividend-paying track record
  • Company generates healthy free cash flow
  • Company maintains a comfortable, low leverage position

CONS

  • Recent results are weak - TTM profit is down 30.8% versus prior year
  • Company has a low return on capital employed of 9.2%
  • Company has a low return on equity of 7.2% over last 3 years
  • Promoter holding has decreased over last 2 years: -3.0pp
  • Company has delivered a poor profit growth of -7.1% over past five years
  • Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY TOTAL MKTNIFTY 500NIFTY SMLCAP 250
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.JUBLPHARMA1025.1046.3716327.910.4956.40-44.982229.4018.658.6911.12
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1,5661,6671,6651,7461,7201,7421,8141,9161,8791,9582,1162,2722,229
1,4171,4381,4591,4871,4801,4631,5341,5831,6111,6251,8331,9512,163
Operating Profit14922820625924027927933226833328332166
OPM %9.52%13.69%12.38%14.84%13.96%16.03%15.40%17.35%14.25%17.00%13.38%14.15%2.98%
91036-1544108-109124-191020
Interest62667173716156534950565654
Depreciation9097951019191919598105121117127
Profit before Tax278988-575001441312061541909417686
Tax %72.18%40.34%39.36%-14.19%3.58%29.00%22.78%26.54%33.59%36.97%40.21%32.22%34.72%
Net Profit00004821021011511021205611956
0.403.944.22-3.6930.446.476.379.716.497.593.527.553.57

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
5,8617,5189,1115,9766,0996,1306,2826,7037,2348,2808,576
4,5165,9997,3724,4284,7024,9745,5065,8026,0617,0207,572
Operating Profit1,3451,5181,7391,5481,3961,1567769011,1741,2601,004
OPM %22.95%20.20%19.09%25.90%22.90%18.86%12.36%13.44%16.22%15.22%11.71%
2540-2444-411-18-100416715
Interest341284220200184145188272240212217
Depreciation291415371340349382554382369440470
Profit before Tax7388599041,01387163028170981614546
Tax %22.10%26.15%36.16%33.08%34.12%34.49%333.45%57.36%14.72%35.27%35.64%
Net Profit575634577678574413-6573836398352
EPS36.9141.2536.8656.3952.4826.00-3.834.8853.1325.22—
Dividend Payout %8.12%7.27%12.48%8.87%9.52%19.23%-130.33%102.47%9.41%19.82%—

COMPOUNDED SALES GROWTH

10 Years:
4%
5 Years:
6%
3 Years:
10%

COMPOUNDED PROFIT GROWTH

10 Years:
0%
5 Years:
-14%
3 Years:
—

STOCK PRICE CAGR

10 Years:
7%
5 Years:
10%
3 Years:
33%
1 Year:
-9%

RETURN ON EQUITY

10 Years:
10%
5 Years:
6%
3 Years:
7%
Last Year:
6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Jul 24

₹ 5

Rs.5.0000 per share(500%)Final Dividend

2025

Jul 25

₹ 5

Rs.5.0000 per share(500%)Final Dividend

2024

Aug 2

₹ 5

Rs.5.0000 per share(500%)Final Dividend

2023

Aug 10

₹ 5

Rs.5.0000 per share(500%)Final Dividend

2022

Aug 11

₹ 5

Rs.5.0000 per share(500%)Final Dividend

2021

Aug 5

₹ 5

Rs.5.0000 per share(500%)Final Dividend

2018

Sep 12

₹ 3

Rs.3.0000 per share(300%)Dividend

2017

Aug 16

₹ 3

27/09/2017 Equity Rs.3.0000 per share(300%)Dividend & A.G.M.

2016

Aug 18

₹ 3

Rs.3.0000 per share(300%)Dividend

2015

Aug 20

₹ 3

Rs.3.0000 per share(300%)Dividend

2026

Aug 3

₹ 5

Rs.5.0000 per share(500%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital16161616161616161616
Minority Interest-47-52000-2-8-13-163
3,4204,0714,7935,5884,7255,2995,3775,4046,2247,058
4,2413,7294,8514,7732,8063,1483,8524,1244,2815,640
Trade Payables7491,1361,0201,0905205688218561,0051,234
5205576398436968028709299901,315
Total Liabilities8,8999,45711,31912,3108,7639,83010,92911,31612,49915,266
5,1075,4015,6486,3404,6094,8715,1835,0915,1766,966
Capital Work in Progress2113004922642782927731,2522,7152,962
10312411569241239256424461
1,2201,3911,4171,8451,1291,2551,3801,2901,1291,232
00000009168921,070
Cash & Bank4602491,3701,4006719841,0149571,0891,268
1,7991,9932,2762,3921,8352,1892,3211,7681,4561,708
Total Assets8,8999,45711,31912,3108,7639,83010,92911,31612,49915,266

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
1,4121,5611,4651,7922,1781,0328659711,0721,227
Cash from Investing-450-618-1,012-327-739-380-544-608488-1,260
Cash from Financing-686-901657-1,050-1,709-33-157-432-1,45395
132-216767166-664425-40-6910762

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
50.6850.6850.6850.6847.6847.6847.6847.6847.68
19.5017.9416.9617.2317.4016.5615.9615.9015.87
4.065.666.987.049.5210.5311.2311.6312.40
Government0.000.000.000.000.000.000.000.000.00
25.7725.7325.3925.0625.4025.2425.1424.8024.05

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-11
General Updates

2026-09-11 - Jubilant Pharmova Limited has informed the Exchange about General Updates

2026-09-01
General Updates

2026-09-01 - Jubilant Pharmova Limited has informed the Exchange about General Updates - Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST

2026-08-29
Copy of Newspaper Publication

2026-08-29 - Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication - Re-lodgement and KYC Updation

2026-08-28
General Updates

2026-08-28 - Jubilant Pharmova Limited has informed the Exchange about General Updates

2026-08-26
Shareholders meeting

2026-08-26 - Jubilant Pharmova Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 26, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

2026-08-23
General Updates

2026-08-23 - Jubilant Pharmova Limited has informed the Exchange about General Updates-USFDA Approval for Line 3, Contract manufacturing facility, Spokane, U.S.A

2026-08-17
Shareholders meeting

2026-08-17 - Jubilant Pharmova Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.

2026-08-11
Copy of Newspaper Publication

2026-08-11 - Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-10
Press Release

2026-08-10 - Jubilant Pharmova Limited has informed the Exchange regarding a press release dated August 10, 2026, titled "The Company has informed the Exchange regarding press release dated August 10, 2026".

News

Recent coverage and analyst commentary for JUBLPHARMA

Loading news…

🤖

AI Stock Analyst

Jubilant Pharmova Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login